|Bid||0.0000 x 3200|
|Ask||2.9300 x 1300|
|Day's Range||2.2200 - 2.8373|
|52 Week Range||1.4600 - 10.4100|
|Beta (3Y Monthly)||1.45|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.20|
Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced positive long term efficacy and safety results from its Phase 1/2a clinical trial evaluating EB-101, a gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). Treatment with EB-101 resulted in sustained wound healing with a favorable safety profile at three years post-treatment.
NEW YORK , Oct. 10, 2019 /PRNewswire/ -- Abeona Therapeutics Inc. (ABEO) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the FDA letter, "clarifying ...
Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (ABEO). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext.
This month, we saw the Abeona Therapeutics Inc. (NASDAQ:ABEO) up an impressive 48%. But will that repair the damage...
NEW YORK, NY / ACCESSWIRE / September 24, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Abeona Therapeutics Inc.("Abeona" or "the ...
Holzer & Holzer, LLC is investigating whether certain statements made by Abeona Therapeutics Inc. complied with federal securities laws.
Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (ABEO). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. On this news, Abeona’s stock price fell $0.39 per share, or 11.96%, to close at $2.87 per share on September 23, 2019.
Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that it has recently received a clinical hold letter from the U.S. Food and Drug Administration (FDA) clarifying that the FDA will not provide approval for the Company to begin its planned Phase 3 clinical trial for EB-101 until it submits to the FDA additional data points on transport stability of EB-101 to clinical sites. Over the last 12 months, the Company has worked closely with the FDA to address and narrow open Chemical, Manufacturing and Controls (CMC) items and has been working to resolve this one item identified in the FDA Clinical Hold Letter.
Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.
Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that it has retained Jefferies LLC as its financial advisor to assist with the review of strategic options focused on advancing the Company’s mission and maximizing stakeholder value. “With four clinical stage programs, a broad pre-clinical pipeline, GMP manufacturing facilities, and a talented team, Abeona remains committed to advancing the promise of genetic medicine,” said João Siffert, M.D., Chief Executive Officer. There is no defined timeline for completion of the review process and the Company does not intend to comment further unless a specific initiative is approved by the Board of Directors, the review process is concluded, or it is otherwise determined that other disclosure is appropriate.
If you own shares in Abeona Therapeutics Inc. (NASDAQ:ABEO) then it's worth thinking about how it contributes to the...
Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -25.64% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Five patients with MPS IIIB treated in the Transpher B Study of ABO-102 gene therapy Positive interim MPS IIIA data showed preservation of neurocognitive development in youngest.
Abeona Therapeutics (ABEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LOS ANGELES, CA / ACCESSWIRE / August 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted (again) as of August 1, 2019. LD Micro has always held the belief that our ...
Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced positive data from its ongoing Phase 1/2 clinical trial evaluating ABO-102, the Company’s investigational one-time, adeno-associated virus 9 (AAV9) gene therapy for Sanfilippo syndrome type A (MPS IIIA). Robust and sustained improvement observed in biomarkers confers additional evidence of a clear biological effect following ABO-102 administration.
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Victor Paulus, Ph.D. as Senior Vice President, Regulatory Affairs. The Company also announced the appointment of Jodie Gillon, M.P.H. as Vice President of Patient Advocacy and Clinical Affairs. Both Dr. Paulus and Ms. Gillon are reporting to Chief Executive Officer João Siffert, M.D.
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]
Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its ABO-202 program. ABO-202, the Company’s novel one-time AAV9 gene therapy for CLN1 disease, is designed to deliver a functional copy of the PPT1 gene to the central nervous system and peripheral organs using a combination of intravenous and intrathecal administrations.